Chardan Capital Reaffirms Buy Rating for Emergent Biosolutions (NYSE:EBS)

Chardan Capital reissued their buy rating on shares of Emergent Biosolutions (NYSE:EBS) in a research note issued to investors on Thursday, AnalystRatings.com reports. The firm currently has a $71.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on the company. Wells Fargo & Co upgraded Emergent Biosolutions from a market perform rating to an outperform rating and upped their price objective for the stock from $61.00 to $64.00 in a research report on Wednesday, September 4th. Cowen restated a hold rating and issued a $67.00 price objective on shares of Emergent Biosolutions in a research report on Thursday. Laidlaw set a $72.00 price objective on Emergent Biosolutions and gave the stock a buy rating in a research report on Wednesday, September 4th. Guggenheim assumed coverage on Emergent Biosolutions in a research report on Thursday, September 12th. They issued a buy rating and a $65.00 price objective on the stock. Finally, ValuEngine upgraded Emergent Biosolutions from a hold rating to a buy rating in a research report on Wednesday, September 4th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $69.00.

NYSE EBS traded down $0.96 during trading hours on Thursday, reaching $54.04. The stock had a trading volume of 350,011 shares, compared to its average volume of 451,394. The stock has a fifty day moving average of $54.01 and a 200 day moving average of $48.08. The stock has a market cap of $3.00 billion, a P/E ratio of 23.19, a price-to-earnings-growth ratio of 0.96 and a beta of 1.55. Emergent Biosolutions has a 52-week low of $39.11 and a 52-week high of $73.89. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.53 and a current ratio of 2.30.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.21 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.58. Emergent Biosolutions had a positive return on equity of 6.68% and a negative net margin of 2.04%. The business had revenue of $311.80 million for the quarter, compared to analyst estimates of $289.16 million. During the same quarter in the prior year, the firm posted $0.55 EPS. The business’s quarterly revenue was up 79.6% compared to the same quarter last year. On average, equities research analysts forecast that Emergent Biosolutions will post 3.04 EPS for the current year.

In other news, Director Kathryn C. Zoon sold 1,509 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $56.12, for a total transaction of $84,685.08. Following the transaction, the director now owns 21,494 shares in the company, valued at approximately $1,206,243.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 14.10% of the company’s stock.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. lifted its position in shares of Emergent Biosolutions by 2.3% during the 2nd quarter. BlackRock Inc. now owns 6,891,631 shares of the biopharmaceutical company’s stock valued at $332,936,000 after buying an additional 155,055 shares in the last quarter. Earnest Partners LLC lifted its position in shares of Emergent Biosolutions by 860.6% during the 2nd quarter. Earnest Partners LLC now owns 1,692,171 shares of the biopharmaceutical company’s stock valued at $81,749,000 after buying an additional 1,516,013 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in shares of Emergent Biosolutions by 2.1% during the 3rd quarter. Rice Hall James & Associates LLC now owns 1,228,791 shares of the biopharmaceutical company’s stock valued at $64,241,000 after buying an additional 25,125 shares in the last quarter. Northern Trust Corp raised its stake in Emergent Biosolutions by 11.0% in the 2nd quarter. Northern Trust Corp now owns 1,001,419 shares of the biopharmaceutical company’s stock valued at $48,378,000 after purchasing an additional 98,858 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Emergent Biosolutions by 11.3% in the 2nd quarter. Invesco Ltd. now owns 862,865 shares of the biopharmaceutical company’s stock valued at $41,685,000 after purchasing an additional 87,799 shares during the last quarter. Hedge funds and other institutional investors own 87.75% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

See Also: Technical Analysis

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.